Facebook
Twitter
LinkedIn
ForwardMelodie Wilson Oldenburg Breast Cancer Symposium
This educational activity will address the multidisciplinary management of breast cancer. Featured speakers are leaders in their respective of breast cancer. Featured speakers are leaders in their respective fields of breast cancer research and treatment who will provide up-to-date summaries of important and diverse topics pertinent to the multidisciplinary management of breast cancer.
ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 3.5 hours of participation for continuing education for allied health professionals.
Target Audience
- Medical Oncologists
- Radiation Oncologists
- Surgical Oncologists
- Residents and Fellows
- Allied Health Professionals
Learning Objectives
At the conclusion of this symposium, participants will have improved awareness and understanding of:
- The importance of multidisciplinary care in the management of breast cancer.
- Options available to assess breast cancer margins intraoperatively in patients undergoing lumpectomy.
- Post-lumpectomy and post-mastectomy radiation therapy approaches to the breast and chest wall.
- Surgical and radiation management options for node-positive breast cancer after lumpectomy and mastectomy.
- Novel systemic therapy approaches for breast cancer, which comprise immunotherapy, targeted therapies including the PI3K/mTOR signaling pathway, and other modalities that may be used in conjunction with standard chemotherapy regimens, hormonal therapy, and targeted H2N therapy.
In accordance with the ACCME® standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved:
| Presenter | Company | Role |
Charles M. Balch, M.D. Professor of Surgery Division of Surgical Oncology Department of Surgery University of Texas Southwestern Medical Center | Merck, Amgen, Novartis | Consultant, Honoraria |
Funda Meric-Bernstam, M.D. Chair, Department of Investigational Cancer Therapeutics Medical Director, Khalifa Institute for Personalized Cancer Therapy Professor, Department of Surgical Oncology Division of Surgery The University of Texas M. D. Anderson Cancer Center | Novartis, AstraZeneca, Taiho, Genentech, Roche Diagnostics, Sysmex |
Research Support, Consultant and Honoraria
|
Elizabeth A. Mittendorf, M.D., Ph.D. Associate Professor of Surgery Department of Surgical Oncology Division of Surgery The University of Texas M. D. Anderson Cancer Center | Galena Biopharmark, Antigen Express, Norwell | Principal Investigator |
Available Credit
- 3.50 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 3.50 Hours of ParticipationHours of Participation credit.